Volume : X, Issue : V, May - 2020

SHORT AND LONG TERM SAFETY AND EFFICACY OF HIGH DOSE ATORVASTATIN IN REDUCING THE LEVEL OF hsCRP AND MAJOR ADVERSE CARDIAC EVENTS IN A GROUP OF PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN EASTERN INDIA.

Dr Ranjan Kumar Mohanty, Dr Satya Narayan Routray, Dr Uttam Kumar Pattnaik

Abstract :

BACKGROUND : Atherosclerosis is an inflammatory process and C reactive protein is an important biomarker of inflammation used clinically. Short term benefit of high dose loading Atorvastatin during periprocedural period in percutaneous coronary intervention {PCI} has been demonstrated in earlier studies. With this background the present study was designed to evaluate the short and long term efficacy of high dose Atorvastatin in patients undergoing PCI in a tertiary care hospital in eastern India. MATERIALS AND METHODS: This study was undertaken in the Department of Cardiology, SCB Medical College, Cuttack between September 2013 to August 2015. All patients undergoing PCI between September 2013 to August 2015 were included in the study. Patients with CKD and CLD and known allergic reaction to statins were excluded from the Study. Patients who developed drug induced liver injury, myalgia and myopathy were also excluded. All patients were followed up for one year. Patients in the Study arm received Atorvastatin 80 mg from the day of procedure, independent of baseline lipid levels, starting before the procedure i.e. immediately after hospitalization and continuing till one month after the procedure with the same dose and then reducing the dose to 40 mg for next 11 months. The patients in control arm received Atorvastatin 20 mg from the day of procedure and continued for 1 year. RESULTS: There were 104 patients in study group and 102 patients in control group. The demographic characteristics of the 2 treatment groups at baseline were similar. All 206 patients were followed up to 1 yr. The hs CRP level surged in day one and came down in both groups by day 7. It was significantly low in study group on day 7 and through out the study period. 2 patients of the 80 mg group & 12 patients of 20 mg group admitted within 1 yr period due to unstable angina/acute coronary syndrome. CONCLUSION: High dose atorvastatin 80 mg in peri–PCI period reduce the hsCRP level and MACE significantly, is very well tolerated in Indian population irrespective of age, sex, bodyweight, co morbid conditions

Keywords :

Article: Download PDF    DOI : 10.36106/ijar  

Cite This Article:

SHORT AND LONG TERM SAFETY AND EFFICACY OF HIGH DOSE ATORVASTATIN IN REDUCING THE LEVEL OF HSCRP AND MAJOR ADVERSE CARDIAC EVENTS IN A GROUP OF PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN EASTERN INDIA., Dr Ranjan Kumar Mohanty, Dr Satya Narayan Routray, Dr Uttam Kumar Pattnaik INDIAN JOURNAL OF APPLIED RESEARCH : Volume-10 | Issue-5 | May-2020

Number of Downloads : 245

References :